FDA expands clearance for Teleflex's Arrow balloon dilatation catheters

Thu, 08/01/2013 - 1:29pm
Mass Device

The FDA gives Teleflex clearance to market more models of its Arrow GPSCath balloon dilatation device suite, which the company picked up during the 2012 Hotspur buyout.

Teleflex (NYSE:TFX) won FDA clearance for expanded sizes and uses of its Arrow GPSCath Balloon Dilatation catheter, a device the company picked up during the 2012 buyout of Hotspur Technologies.

The FDA win lets Teleflex sell the catheter in new 80 cm lengths and in a higher burst pressure rating. The Limerick, Pa.-based device company calls the Arrow GPS a "dual-function" balloon catheter because of its ability to widen arteries while injecting fluids.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.